Introduction {#S0001}
============

Mucosa-associated lymphoid tissue (MALT) lymphoma is a subtype of non-Hodgkin's lymphoma (NHL), accounting for approximately 5% of all NHL.[@CIT0001] MALT lymphoma can occur anywhere external to outside of the lymph nodes, such as in the gastrointestinal (GI) tract, thyroid gland, salivary glands, lungs, and breast. The most common site of occurrence of MALT lymphoma is the stomach in 60% to 75% of cases, followed by small intestine, ileum, cecum, colon, and rectum. Involvement of the esophagus has also been reported, as well as the extra-intestinal sites including lungs, ocular adnexa, lung, breast, and skin.[@CIT0002] Primary malignant lymphoma in the large intestine is rare, accounting for about 1% of GI MALT lymphomas and less than 1% of all colon malignancies.[@CIT0003] MALT lymphoma is known to have a good prognosis, but it may exhibit less response to chemotherapy.[@CIT0004] Thus, treatment methods for MALT lymphoma are being studied, different to those for conventional lymphoma.[@CIT0005]

Although colorectal MALT lymphoma is the third most common in GI MALT lymphoma, because of the rarity, its management has not been standardized and interpretation of outcomes following various therapeutic approaches is difficult. This manuscript reviews the English literature on primary colon and rectum MALT lymphoma, describes the treatment failure cases, and analyzes the risk factors.

Methods {#S0002}
=======

We reviewed case reports on colorectal lymphoma from 1993 to 2017. A PubMed search of the English medical literature was conducted using the search words "colon", "rectum", and "Maltoma" or "MALT lymphoma" as filters. Through the review, 65 case reports were found, of which 15 case reports were excluded, due to being written in languages other than English, poorly documented cases, and combined colonic disease such as adenocarcinoma or inflammatory bowel disease. Subsequently, 67 patients reported in 50 studies were included from PubMed search ([[supplementary data]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=214197.pdf)). In addition, we retrospectively reviewed the medical records of 6 patients who were pathologically diagnosed and treated (surgery or chemotherapy or endoscopic mucosal dissection; EMR) with colon or rectal MALT lymphoma at OO University-affiliated hospitals (Kangnam Sacred Heart Hospital, Kangdong Sacred Heart Hospital, Chuncheon Sacred Heart Hospital, Dongtan Sacred Heart Hospital, Hangang Sacred Heart Hospital, and Hallym Sacred Heart Hospital) between January 2005 and February 2015 via PubMed. Approval for all research-related activities was obtained from the Institutional Review Board of the Hallym University (IRB 2019--07-016). As all data were accessed through publicly available sources, patient consent was not required. The research followed ethical considerations involved and adhered to the principles enunciated in the Declaration of Helsinki.

Assessment of clinical characteristics and recurrence {#S0002-S2001}
-----------------------------------------------------

Patients\' demographic information and characteristics of the disease and its treatment were tabulated. Patient factors included age, sex, tumor location, tumor size, number of tumors, other GI tract involvement, symptoms, size, and status of *Helicobacter pylori* infection, comorbidity, and diagnosis method. The *H. pylori* testing modalities included individual or combination evaluation of urea breath test, *H. pylori* culture, histologic biopsies (gastric and/or rectal), stool antigen, serum antibody, and rapid urease test ([Figure 1](#F0001){ref-type="fig"}). Tumor size was based on the longest diameter. Tumor location was categorized as rectum, colon (ascending colon, transverse colon, and sigmoid colon). Symptoms included fecal occult blood, hematochezia or melena, abdominal pain or discomfort, defecation problem such as prolapsed mass, constipation, and others with diagnosed as screening colonoscopy or intussusceptions etc. We categorized tumors into two groups, solitary and multiple. Other GI tract involvement was defined as tumor found in stomach, duodenum, ileum or different colonic site. We divided colon into four quadrants (ascending, transverse, descending/sigmoid, rectum). The different colonic sites were defined as location in a quadrant of colon other than quadrant of the origin of tumor. The diagnosis was done by endoscopic biopsy, excisional biopsy (EMR or transanal excision), and surgery. The treatment methods were also retrieved from case reports or medical records. Treatment variables included radical surgery, local excision (EMR or transanal excision), chemotherapy, radiation, *H. pylori* eradication (antibiotics therapy) or combination.Figure 1The endoscopic finding of *H. pylori* infection in the stomach.

The chemotherapy regimens were diverse, including CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), MACOPB (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone). And rituximab alone as a single agent had also been used. In patients treated with radiation, the radiation range varied, from 30 to 45 Gy. *H. pylori* eradiation regimens administered included 7-day course of omeprazole, amoxicillin, and metronidazole, 7 days of rabenprazole, amoxicillin, and clarithromycin, a 10-day course of amoxicillin and clarithromycin, 10 days of levofloxacin repeated three times, a 14-day course of omeprazole, amoxicillin, and clarithromycin, 14 days of amoxicillin and clarithromycin, and undocumented days of amoxicillin and clarithromycin. Dose of medications and times of administration per day varied widely, drug doses were: lansoprazole 30 and 60 mg, rabenprazole 20 mg, amoxicillin 1000 and 1500 mg, clarithromycin 400, 500, 600, and 800 mg, and levofloxacin 300mg.

Complete remission (CR) was defined as the disappearance of the lesion(s) on endoscopic evaluation and histologic diagnosis of MALT with biopsy. Remission failure was defined as no response or partial response after second-line treatment, defined as the additional treatment due to failure of the first-line treatment. Recurrence was defined as new appearance of the tumor in the same lesion or other GI or another organ during the follow-up after CR. Treatment failure comprised remission failure and tumor recurrence.

Statistical analysis {#S0002-S2002}
--------------------

Summary statistics were represented by counts (percentage) or median (range), where appropriate. Chi-squared test was used to compare recurrence among treatment methods (radical surgery vs local excision vs chemotherapy vs radiation vs antibiotics vs combination therapy). Univariable analysis was performed for risk factor analysis of treatment failure using chi-squared test. Comparisons between population medians were performed using a Kruskal Wallis test for non-normally distributed variables for normally distributed variables. Logistic regression model was used to further investigate the association between treatment failure and clinical factors for multivariable analysis. All statistical analyses were performed using SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA). All reported *p*-values were two-sided, with statistical significance set at *p*\<0.05.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

Here, we newly report 6 colorectal MALT lymphoma cases. Tumors were found in rectum in two cases and in four cases in colon (ascending 3, sigmoid 1). Four cases were incidentally found by screening colonoscopy, one case was related to occult blood positive and the other had abdominal discomfort. None of them had B symptoms and any history of inflammatory bowel disease. Surgery was performed in four cases, while there were two other cases where EMR and chemotherapy was done respectively. In more detail, local excision at rectum was performed in two cases and right hemicolectomy at ascending colon in the other two cases. One case showed remission failure with first-line treatment but, CR was achieved after adjuvant chemotherapy. None of them had recurrence ([Table 1](#T0001){ref-type="table"}).Table 1Clinical characteristics of colorectal MALT lymphoma cases in six Hallym medical institutesNumberAgeSexInitial symptomLocationTumor\
numberMax\
tumor size (mm)ComorbidityTreatmentRemissionFollow-up**1**59FScreening colonoscopyRectum120Y (DM)Transanal excisionY17**2**87FOccult bloodRectum410Y (HTN)Transanal excisionY6**3**44MScreening colonoscopyAscending colon11Y (DM/HTN)ChemotherapyY63**4**76MScreening colonoscopySigmoid115Y (hypopituitary)EMRY61**5**79MAbdominal discomfortAscending colon120Y (megaloblastic anemia)Right hemicolectomyY14**6**66FScreening colonoscopyCecum113NRight hemicolectomyY24[^1]

A total of 73 patients with colorectal MALT lymphoma were included in our study, data of 6 were retrieved from our multicenter hospital and 67 were from 50 case reports. The median age of disease was 62 (range 26--87). 48 patients (65.8%) were women and the rest (25) were men (34.2%), indicating that women's incidence rate was two times as high as men. Most patients were diagnosed with MALT lymphoma in rectum (54, 74.0%), 10 patients (13.6%) in right colon, 3 patients (4.1%) in the transverse colon, and 6 (8.2%) patients in the sigmoid colon. Most patients had solitary type (70.0%), while 22 cases showed multiple tumors (30.0%). These colorectal MALT lymphomata developed simultaneously in the colorectum and other intestines such as stomach or duodenum (2), other quadrant of colon (7) in nine cases (12.3%). The most common symptom was hematochezia or melena (38.4%), though, there were cases with no symptoms before the disease was detected through colonoscopy (16.4%). The median tumor size was 20 mm (2\~90 mm). The test for *H. pylori* infection was done in 44 cases and it was positive in 14 cases (19.2%). Pathological confirmation was done by colonoscopic biopsy (46.6%), 20 patients were diagnosed by endoscopic excisional biopsy (27.4%), and 19 patients (26%) were diagnosed surgically without a biopsy. The mean follow-up period was 18.5 months (2--120 months) after treatment ([Table 2](#T0002){ref-type="table"}).Table 2Demographic and clinical characteristics and diagnostic informationN=73 (%)**Age**62 (54--72)**Male: Female**25:48**Tumor location** Rectum54 (74) Colon (ascending: transverse: sigmoid)10:3:6 (26)**Number of tumors** Solitary51 (70) Multiple22 (30)**Other GI tract involvement** Yes9 (12.3) No64 (87.6)**Symptom** Fecal occult blood11 (15.1) Hematochezia or melena28 (38.4) Abdominal pain or discomfort8 (11) Defecation problem (prolapsed mass, pain)6 (8.2) Screening colonoscopy with no symptom12 (16.4) Others8 (11)**Size^a^ (mm)**20 (10--36)***H. pylori* infection**^**b**^ **(44 cases)**14 (19.2)**Comorbidity** Yes23 (31.5) No50 (68.5)**Diagnosis method** Endoscopic biopsy34 (46.6) EMR or transanal excision20 (27.4) Surgery19 (26.0)**Median follow-up (month)^c^**18.5 (9--34)[^2][^3]

Therapeutic modality {#S0003-S2002}
--------------------

The therapeutic modalities and recurrence rates are described in [Table 3](#T0003){ref-type="table"}. The following strategies were used for 73 patients as the first-line treatment: surgery (19 cases), local resection (19 cases), chemotherapy (13 cases), radiation therapy (5 cases), antibiotics therapy including *H. pylori* eradication (15 cases), and no treatment (2 cases). The overall remission rate was 95.8%, not different among patients treated by tumor resection, chemotherapy, radiation therapy, and antibiotics (92.1% vs 92.3% vs 80% vs 80%, *p*=0.29). Tumor recurrence occurred in 5 (6.8%), treatment variables did not significantly affect the recurrence rate (*p*=0.20).Table 3Therapeutic modality with treatment responseN (%)No response or partial response\
with first-line treatment (%)*p*Recurrence (%)*p***First-line treatment**0.290.20Radical surgery19(26)1(5.3)1 (5.3%)Local excision (EMR + transanal excision)19(26)1(5.3)0Chemotherapy13(17.8)1(7.7)3 (23.1)Radiation5(6.8)1(20)0Antibiotics (or*H. pylori*eradiation)15(20.5)3(20)1 (6.7)Untreated2(2.7)1(50)0[^4][^5]

Among the 73 patients, 8 patients showed no response or partial response and needed second-line treatment ([Table 4](#T0004){ref-type="table"}). There were 2 cases of remission after second-line treatment, following additional tumor resection after the first-line chemotherapy or radiation therapy. Two patients who did not respond to *H. pylori* treatment had additional radiation therapy, but only one of them achieved remission. One patient who had been treated with *H. pylori* eradication achieved remission after additional antibiotic treatment. There was one case of residual tumor in the resection margin after a tumor excision, which showed remission after adjuvant chemotherapy. There were two cases in whom no treatment was implemented at all. Tumor disappeared in one of them, while it remained uncured in the other. Overall, remission failure occurred in three cases (4.1%). Tumor recurred in 5 patients (6.8%). Three patients showed local recurrence and two patients showed systemic recurrence. In one case of local recurrence, chemotherapy was implemented with multiple rectal MALT lymphomas, but the tumor recurred in the same site four months thereafter. Another case of local recurrence, protruding masses through sigmoid colon had been removed by excision and subsequent chemotherapy was implemented. In the follow-up colonoscopy, this patient showed an abnormal lesion and underwent EMR, and was then diagnosed with MALT lymphoma. In the last case of local recurrence, a rectal single polypoid mass was treated with *H. pylori* eradication, but 18 months later, the tumor recurred in the same site. In one case of systemic recurrence, gastric, duodenal, and rectal lesions occurred at the time of initial diagnosis, where chemotherapy was initially performed but the tumor recurred in the same sites. In the other case of systemic recurrence, the tumor recurred on the gingiva of a patient who received chemotherapy for solitary rectal MALT lymphoma.Table 4Description of treatment failure casesAuthorYearCountryAgeSexInitial symptomLesion locationFirst-line treatmentSecond-line treatmentRemissionRecurrence**No regression**1Matsumoto T et al[@CIT0029]1998Japan60MHematocheziaRectum, A-colon, T-colon, S-colonEMRNoneNone-2Navarra G et al[@CIT0019]200354FBowel obstructionRectumNeoadjuvant chemotherapySphincter saving operationYesNone3Kojima et al[@CIT0015]2005Japan66FHematocheziaRectumEMRRTNoneYes4Piotrowski R et al[@CIT0018]2008USA83FAnemiaS-colonRadiationEMRYesNone5Amouri A et al[@CIT0017]2009French46FRectal bleedingRectumHPERTNoneNone6Park JH\
\[Hallym case 7\]2010Korea59MAbdominal painCecumSurgeryChemoNEDNone7Chahil N et al[@CIT0030]2011USA78FHematocheziaRectumHPERTYesNone8Matsumoto T et al[@CIT0031]2013Japan80WFecal occult bloodCecum, A-colonHPEAntibioticsYesNone**Recurrence**1Bschorer R et al[@CIT0032]1993Germany56MPainful defecationRectumChemoYesYes2Gianni L et al[@CIT0033]1998Italy56MNDRectum, Gastrum, DuodenumChemo + HPEYesYes3Gavioli M et al[@CIT0016]2001Italy45MHematocheziaRectumChemoYesYes4Tanaka S et al[@CIT0034]2003Japan62MScreeningRectumSurgery + Chemo (CHOP; S-colon)YesYes5Nosaka K et al[@CIT0020]2014Japan74MNDRectumHPEYesYes[^6]

Risk factor analysis of treatment failure {#S0003-S2003}
-----------------------------------------

In univariate analysis with chi-squared test, male sex, multiple tumors, and first-line treatment failure were significant high-risk factors for treatment failure (*p*=0.02, *p*=0.04, *p*=0.04, respectively) ([Table 5](#T0005){ref-type="table"}). In multivariate analysis, male sex had a 7.69-fold increased risk, first-line treatment failure 2.50-fold increased risk, and multiple tumors 6.80-fold increased risk for treatment failure (*p*=0.04, *p*=0.03, *p*=0.02, respectively) ([Table 6](#T0006){ref-type="table"}).Table 5Univariable analysis of risk factors for treatment failure (second-line treatment failure cases and tumor recurrence)Well treated\
(N=65)Treatment failure (N=8)*p***Age**61.75±13.262.12±10.50.94**Sex**0.02 Female462 Male196**Tumor number**0.04 Single483 Multiple165**Tumor size^a^ (median)**20(10--34)30(15--82)0.23**Disease extent**0.67 Colon181 Rectum477**Other organ involvement**0.61 No556 Yes102**First-line treatment remission**0.04 Yes605 No53**Surgery**0.11 Only362 Others296**Chemotherapy**0.49 Only102 Others556**Radiation**1.00 Only50 Others608**Antibiotics**0.66 Only132 Others526**Morbidity**1.00 None466 Yes192**Combined^b^**0.06 Monotherapy554 Combined52[^7] Table 6Multivariable analysis of risk factors for treatment failure (second-line treatment failure cases and tumor recurrence)OROR 95% CI*p***Male (vs female)**7.691.15--500.04**Tumor number (multiple vs single)**6.800.159--39.8750.03**First-line treatment failure**2.501.41--1000.02[^8]

Discussion {#S0004}
==========

In this study, we found that the failure of first-line treatment, multiple tumors, and male sex were associated with a risk of treatment failure. As primary colonic MALT lymphoma is most commonly associated with GI bleeding, surgical resection is a good option for symptomatic treatment of colorectal MALT lymphoma, although this treatment option did not show a significant difference in remission of first-line treatment.

MALT lymphoma was first described by Isaacson and Wright in 1983.[@CIT0002] Although the pathogenesis of MALT lymphoma has not been clearly elucidated, several etiological factors have been postulated to explain this rare disease. There are two types of MALT lymphoma, one that originates from normally present lymphoid tissue like Peyer patches in the gut, and the second that arises from acquired lymphoid tissue that develops in response to inflammation in the setting of infection/autoimmune disease/inflammatory bowel disease/immunosuppression.[@CIT0006]

The colonic MALT lymphomas are predominantly seen in the sixth decade of life. The median age of presentation is 62. Although there is no difference among the sexes according to one review,[@CIT0007] female predominance is seen in a 2:1 ratio compared to males. According to previous reports, the majority of colorectal lymphomas are known to develop in the cecum or ascending colon, and \>70% are proximal to the hepatic flexure.[@CIT0008] However, based on an analysis of 73 cases, the most common site of colonic MALT lymphoma is the rectum (74.0%) and second site was proximal to the hepatic flexure (13.7%). Clinical presentation ranges from asymptomatic and discovered only through screening colonoscopy to presentation with non-specific abdominal discomfort to more dramatic presentation that includes GI bleeding, defecation problem or pain sometimes combined with intussusception or obstruction. MALT lymphoma of the colon sometimes occurs simultaneously at other sites in other GI tracts such as stomach, duodenum or other quadrant of colon (12.3%); therefore, at the time of diagnosis, synchronous lesions should also be ruled out. So, staging for MALT lymphomas should include gastroscopy, colonoscopy, bone marrow biopsy, and CT of thorax and abdomen. When grossly visible in colonoscopy, most MALT lymphomas are observed as a single mass with protrusion, ulceration or sessile or infiltrated.[@CIT0009] Most commonly, a single polypoid lesion (70%) is seen, but multiple polypoid lesions are also reported (30%) and should be distinguished during colonoscopy ([Figure 2](#F0002){ref-type="fig"}). The median tumor size was 20 mm (2--90 mm), so it could easily be treated by using EMR.[@CIT0010],[@CIT0011] In this analysis, colonic MALT lymphoma was diagnosed during surgery (26%) or endoscopic biopsy (46.6%). In the case of endoscopic biopsy, the submucosa must be collected, so, sometimes EMR was preferred for biopsy (27.4%).Figure 2The feature of multiple polypoid MALT manifestations in the rectum.

NHL, including MALT-type can be evaluated using the Ann-Arbor Staging Classification,[@CIT0012] which focuses on the number of tumor sites (nodal vs extranodal), location, and the presence or absence of systemic B symptoms (weight loss, night sweating, unexplained persistent or recurrent fever). Colonic MALT lymphoma is mostly localized and systemic B symptoms are rare.[@CIT0013] Furthermore, because of limited data with cases reports, we only classified as single or multiple and distant organ involvement or not, instead of using this classification. Our data showed, 30% of colonic MALT lymphomas were multiple tumors, and 12.3% involved another GI tract organ. Most cases did not show systemic B symptoms. Diagnosis uses tissue immunohistochemistry and can be used to help distinguish MALT lymphomas from other small B-cell NHLs ([Figure 3](#F0003){ref-type="fig"}). B-cell-associated antigens such as CD19, CD20, CD22, and CD79a are usually expressed in such MALT lymphoma specimens.[@CIT0014]Figure 3Polymorphous immunoblots exhibiting prominent nucleoli within irregular and vesicular nuclei (H&E ×400).

For colonic MALT lymphoma, there is no standardized therapy and the best treatment modality has long been debated. In most cases, tumor resection or chemotherapy is used as the primary treatment. Remission rates of resection and chemotherapy were higher than 90%. Radical surgery or local excision showed 5.3% treatment failure at first-line treatment. We think surgery can be a good remedy for melena and hematochezia, which are the most common symptoms in colonic MALT lymphoma. Most of the cases treated with surgery had combined symptoms such as bleeding or obstruction related with huge mass. Also, it is known that for other locations, radiation is a very effective treatment modality for MALT lymphoma. However, only five cases with colonic MALT lymphoma were treated with radiation therapy. For the colonic MALT lymphoma, radiation therapy is considered to be limited in view of reduced bowel motility due to problems such as radiation colitis.

The results of the analysis of treatment failure including 3 patients who did not achieve CR and 5 patients who had recurrence after treatment were reported to be comparatively inferior to men and even in the cases of multiple lesions. On multivariate analysis for treatment failure, multiple lesions were analyzed as a risk factor. Kojima et al[@CIT0015] reported that in MALT lymphoma of the rectum in which multiple lesions were found, EMR was done and radiation therapy was added, but remission could not be achieved. Patients treated with chemotherapy for multiple rectal MALT lymphomas also showed recurrence in the same site.[@CIT0016] The reason for treatment failure of multiple tumor type is believed to be the possibility of malignancy hidden in the surrounding lymphoid tissue which manifests as multiple tumors. Therefore, some treatment methods for multiple tumors seemed to have limited abililty to remove all the hidden cancer cells. Interestingly, our data showed that patients without remission following first-line treatment had a high rate of treatment failure. Among 8 patients with failed primary treatment, only 5 patients (62.5%) achieved remission after the second treatment. Therefore, the choice of first-line treatment is very important for treatment of colonic MALT lymphoma. In the case of patients with first-line remission failure, second-line treatment should be considered to select the method for complete removal of primary tumor. When we reviewed final remission failure cases, two patients selected radiation treatment for second-line treatment, but it seemed to be meaningless.[@CIT0015],[@CIT0017] Regarding two risk factors, we should select the best treatment method to achieve complete eradication of primary tumor at first-line treatment. Interestingly, one of the recent articles introduced a new treatment strategy, curative endoscopic resection of a large polypoid MALT lymphoma after downsizing tumors with radiotherapy or chemotherapy. This treatment reduces the size or extent of tumor and increases the possibility of complete removal of the tumor, and can broaden options for treating colonic MALT lymphoma.[@CIT0018],[@CIT0019]

While surgery or chemotherapy was chosen as the first-line treatment in most cases, there are rare cases where complete resolution with *H. pylori* therapy was achieved. Nosaka et al[@CIT0020] reported a case of a patient with rectal MALT lymphoma treated with *H. pylori* eradication, but the case ended up with local recurrence in the same area within 18 months. Our data showed that antibiotic treatment for *H. pylori* eradication is not inferior to other treatments such as surgery, radiation, or chemotherapy, even though it has shown a lower remission rate than others; 80% compared to 90%. Further antibiotics prescription was helpful for CR of some failure cases that had previously been treated for *H. pylori*. This convinced us that colonic MALT lymphoma is also associated with viral infection. Although the pathogenesis of MALT lymphoma in the colorectum has not been elucidated yet, antiviral therapy seems to be effective for the treatment of colorectal MALT lymphoma. However, there have been no previous studies demonstrating the existence of certain mutations as described previously, or virus strains. Although the question of why a certain proportion of colorectal MALT lymphomas may respond to antibiotics remains unanswered, several crucial findings may support the following speculations: 1) HPE prescriptions can also eradicate other bacteria or bacteria similar to *H. pylori* associated with the development of human colon MALT lymphoma.[@CIT0021],[@CIT0022] For example, Morgner et al[@CIT0023] found that five gastric MALT lymphoma patients with documented *Helicobacter heilmannii* infection achieved CR after 14 days of omeprazole and amoxicillin therapy. 2) HPE regimens can also eradicate intestinal microorganisms associated with the development of colorectal MALT lymphoma. Lecuit et al[@CIT0024] found that small intestinal MALT lymphoma patients with documented *Campylobacter jejuni* infection achieved CR with triple antimicrobial therapy (amoxicillin, metronidazole, and clarithromycin) with omeprazole. 3) In addition to eradicating HP and HP-like bacteria, clarithromycin has direct anti-neoplastic or immunomodulatory effects.[@CIT0025],[@CIT0026] In a B-cell lymphoma cell line derived from a BALB/c mouse model, O'Hara et al[@CIT0027] showed that clarithromycin inhibited cell viability and induced apoptosis through down-regulating BCL-2 expression. Mizunoe et al[@CIT0028] showed that macrolides, either clarithromycin or azithromycin, caused apoptosis of activated lymphocytes through attenuation of BCL-XL expression.

This study has some limitations: first, the number of patients was insufficient due to the very rare disease, and was only reported as case reports. Secondly, the data lack consistency as it was collected through multicenter case reports, thus, the accuracy of the data is not guaranteed. Lastly, long-term follow-up results may not be included although we added the analysis of treatment failure. However, our study may still be meaningful since there are no previous studies that have involved separate reviews of treatment failure for colonic MALT lymphoma.

Conclusion {#S0005}
==========

There is a standard established treatment for gastric MALT lymphoma, but this is not the case for colorectal MALT lymphoma. Although colonic MALT lymphoma is an easily curable disease with a relatively low recurrence rate, success of treatment cannot be guaranteed without success of first-line treatment. A careful approach is needed in designing the first-line treatment strategies for patients with multiple tumors or for males. This is because the prognosis for multiple tumors and males is likely to be poor although the number of failure cases is too small to draw definitive conclusions. This finding deserves further validations by investigators in their research.
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[^1]: **Abbreviations:** Number, number of tumors; Y, yes; N, no; DM, diabetes mellitus; HTN, hypertension; EMR, endoscopic mucosal resection.

[^2]: **Notes:** Tabulated with forty-one cases in PubMed case reports and 6 Hallym hospital cases; ^a^analyzed with 50 patients who were commented with size in case reports. ^b^*H. pylori* test was done in 44 patients analyzed with 50 patients who were commented with last follow-up in case reports.

[^3]: **Abbreviation:** *H. pylori, Helicobacter pylori.*

[^4]: **Notes:** 67 of these patients received monotherapy and 6 others received combined therapy in first-line treatment. Among those who received combined therapy, two patients were treated with *H. pylori* eradication after tumor resection. Two were treated with chemotherapy or radiotherapy after *H. pylori* eradication. For the other two patients, concurrent chemotherapy was implemented, one received antibiotic therapy after the chemotherapy. The overall remission rate was not different among patients treated with tumor resection, chemotherapy, radiation therapy, and antibiotics (92.1% vs 92.3% vs 80% vs 80%, *p*=0.29) and treatment variables did not significantly affect the recurrence rate (*p*=0.20).

[^5]: **Abbreviations:** EMR, endoscopic mucosal resection; *H. pylori, Helicobacter pylori.*

[^6]: **Abbreviations:** EMR, endoscopic mucosal resection; HPE, *Helicobacter pylori* eradication; APR, abdominoperineal resection; chemo, chemotherapy; RT, radiotherapy; F, female; M, male; A-colon, ascending colon; T-colon, transverse colon; S-colon sigmoid colon; NED, no evidence of disease.

[^7]: **Notes:** ^a^Only 50 patients described; ^b^only patients with primary remission.

[^8]: **Abbreviations:** OR, odds ratio; CI, confidence interval.
